KRAS and non-small cell lung carcinoma: Additionally, twenty-seven studies [8–11, 15, 16, 18–24, 26–28, 31, 32, 34, 35, 39, 40, 42, 43, 47, 50, 51] including 9,383 both KRAS and EGFR assessable patients investigated the prognostic and predictive value of KRAS mutation in EGFR wild-type NSCLC.